Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data

Table 1

Regimen used in elotuzumab group and carfilzomib group.

Arm	Regimen
Elotuzumab; group	Elotuzumab: 10 mg/kg on day 1, 8, 15, and 22 for the initial two cycles; 10mg/kg on day 1 and 15 for the following cycles.
	Lenalidomide: 25 mg/kg on days 1-21 for each cycle.
	Dexamethasone: 40 mg orally for the week without elotuzumab; 8 mg intravenously plus 28 mg orally on the day of elotuzumab administration.
	Administered until withdrawal of consent, disease progression, or the occurrence of unacceptable toxic effects.
Carfilzomib; group	Carfilzomib: 10 min infusion on days 1, 2, 8, 9, 15, and 16 (starting dose, 20 mg/m2 on day 1 and 2 of cycle 1;target dose, 27 mg/m2 thereafter) for cycles 1-12 and on days 1, 2, 15, and 16 during cycles 13 through 18.
	Lenalidomide: 25 mg/kg on days 1-21 for each cycle.
	Dexamethasone: 40 mg administered on days 1, 8, 15, and 22.
	Administered until withdrawal of consent, disease progression, or the occurrence of unacceptable toxic effects.